The HALO PathWay™ for Prostate Cancer Saves Patient's Lives Through Early Detection

Prostate cancer is the second leading cause of cancer death for men. 1 in 9 men will be diagnosed with prostate cancer in their lifetime. According to the American Cancer Society, while most prostate cancers occur in men without a family history of the disease, having a father or brother with prostate cancer more than doubles a man’s risk of developing it. The risk increases with every additional family member affected by the disease, particularly if the relative was young when the cancer was found.
HALO Diagnostics™ is the leader in early disease detection using precision diagnostics. Now offered is the HALO Experience™, a genetic test ensemble that provides patients and providers with the most advanced imaging, biomarker testing, genetic testing, and predictive analysis of a patient’s risk of prostate cancer and helps to guide those at high risk through additional screening and treatment, if necessary. The result is a one-stop patient and referring physician experience that has the potential to save lives with precision diagnostics. To learn more about the HALO PathWay™, visit www.halodx.com...
Men with a family history of breast, endometrial, ovarian, colon, pancreatic, or prostate cancer, could be at risk for developing prostate cancer themself. Ethnicity can also play a big part in one’s chances of getting prostate cancer. African American men are 1.8 times more likely to be diagnosed with prostate cancer, and 1 in 40 Ashkenazi Jewish patients carry a BRCA mutation, resulting in a higher risk of prostate cancer.
The genetic testing identifies genetic mutations that put patients at a higher risk of developing cancer. To learn more about genetic mutations, visit www.halodx.com...
Depending on your risk factors, you may begin screening for prostate cancer at an early age, though general guidelines recommend starting at age 55. The Prostate Specific Antigen (PSA) screening test is the standard test to identify clinically significant prostate cancers. Dr. John Feller, HALO’s Chief Medical Officer, explains that this test alone misses 15% of clinically significant prostate cancers. When combined with advanced imaging and germline genetic testing through the HALO Way™, less than 1% of clinically significant prostate cancer is missed.
Curious to learn more about PSA levels and the PSA test? Read more in our blog that features a PSA Range Finder to compare your age and PSA level against the baseline for your age: www.halodx.com...
Patients with a high PSA level require further screening. 99% of high-grade cancers are detected when the mpMRI, PSA Density, and urine biomarkers are used together. By combining imaging, lab, and genetic test results, HALO can identify your personal cancer risk. If a high risk is found, the PrecisionDx Report will provide recommendations for next steps. Dr. Feller also notes, “When we combine those three things, it turns out we miss like 1% or less of clinically significant prostate cancers, so we decrease the blind spots of each of these tests by combining them.”
Too many men are diagnosed too late. When detected early, the 5-year survival rate for men diagnosed with prostate cancer is greater than 99%. Cancer that is diagnosed earlier requires less invasive surgery and treatment for improved outcomes.
Prostate cancer is highly treatable, and with the appropriate education around the steps towards early detection with precision diagnostics, most men can continue to lead active, healthy lives many years after diagnosis.
HALO Diagnostics is the leader in early disease detection using precision diagnostics. The company’s outpatient Precision Diagnostic Centers are reshaping the healthcare ecosystem by integrating advanced imaging, digital pathology, molecular genomics, and predictive analytics under one roof, in a lower-cost, outpatient setting. HALO makes early-stage disease screening and diagnosis faster and more convenient for patients and physicians alike. With a HALO PathWay™ for breast, prostate, neuro, and cardiac disease, HALO is increasing early disease detection and saving lives. HALO currently serves one million patients, a number expected to triple by 2024. For more information visit www.halodx.com
#prostatecancerawareness #menshealth #genetictesting #screeningsaveslives #earlydetection
Subscribe to HALO Diagnostics™’ TH-cam Channel
/ @haloprecisiondiagnostics
For more content, follow us on social media
Facebook: / halodx
LinkedIn: / 31464503
Twitter: / haloprecisiondx
Instagram: / haloprecisiondx